Sartorelli A C
Br J Cancer. 1985 Sep;52(3):293-302. doi: 10.1038/bjc.1985.193.
Most drugs available for cancer chemotherapy exert their effects through cytodestruction. Although significant advances have been attained with these cytotoxic agents in several malignant diseases, response is often accompanied by significant morbidity and many common malignant tumours respond poorly to existing cytotoxic therapy. Development of chemotherapeutic agents with non-cytodestructive actions appears desirable. Considerable evidence exists which indicates that (a) the malignant state is not irreversible and represents a disease of altered maturation, and (b) some experimental tumour systems can be induced by chemical agents to differentiate to mature end-stage cells with no proliferative potential. Thus, it is conceivable that therapeutic agents can be developed which convert cancer cells to benign forms. To study the phenomenon of blocked maturation, squamous carcinoma SqCC/Y1 cells were employed in culture. Using this system it was possible to demonstrate that physiological levels of retinoic acid and epidermal growth factor were capable of preventing the differentiation of these malignant keratinocytes into a mature tissue-like structure. The terminal differentiation caused by certain antineoplastic agents was investigated in HL-60 promyelocytic leukaemia cells to provide information on the mechanism by which chemotherapeutic agents induce cells to by-pass a maturation block. The anthracyclines aclacinomycin A and marcellomycin were potent inhibitors of N-glycosidically linked glycoprotein biosynthesis and transferrin receptor activity, and active inducers of maturation; temporal studies suggested that the biochemical effects were associated with the differentiation process. 6-Thioguanine produced cytotoxicity in parental cells by forming analog nucleotide. In hypoxanthine-guanine phosphoribosyltransferase negative HL-60 cells the 6-thiopurine initiated maturation; this action was due to the free base (and possibly the deoxyribonucleoside), a finding which separated termination of proliferation due to cytotoxicity from that caused by maturation.
大多数可用于癌症化疗的药物通过细胞破坏发挥作用。尽管这些细胞毒性药物在几种恶性疾病中取得了显著进展,但治疗反应往往伴随着明显的发病率,而且许多常见的恶性肿瘤对现有的细胞毒性疗法反应不佳。开发具有非细胞破坏作用的化疗药物似乎是可取的。有大量证据表明:(a)恶性状态并非不可逆转,而是一种成熟改变的疾病;(b)一些实验性肿瘤系统可被化学试剂诱导分化为无增殖潜力的成熟终末细胞。因此,可以想象能够开发出将癌细胞转化为良性形式的治疗药物。为了研究成熟受阻现象,在培养中使用了鳞状细胞癌SqCC/Y1细胞。利用该系统能够证明生理水平的视黄酸和表皮生长因子能够阻止这些恶性角质形成细胞分化为成熟的组织样结构。在HL-60早幼粒细胞白血病细胞中研究了某些抗肿瘤药物引起的终末分化,以提供关于化疗药物诱导细胞绕过成熟阻滞机制的信息。蒽环类药物阿克拉霉素A和马塞洛霉素是N-糖苷连接糖蛋白生物合成和转铁蛋白受体活性的有效抑制剂,也是成熟的有效诱导剂;时间研究表明,生化效应与分化过程相关。6-硫鸟嘌呤通过形成类似核苷酸在亲本细胞中产生细胞毒性。在次黄嘌呤-鸟嘌呤磷酸核糖转移酶阴性的HL-60细胞中,6-硫嘌呤引发成熟;这种作用归因于游离碱(可能还有脱氧核糖核苷),这一发现将细胞毒性导致的增殖终止与成熟导致的增殖终止区分开来。